Sunesis and Royalty Pharma Announce $25 Million Vosaroxin Royalty Agreement

New York, NY and South San Francisco, CA – March 29, 2012 - Royalty Pharma and Sunesis Pharmaceuticals (NASDAQ:SNSS) today announced that Royalty Pharma has agreed to pay Sunesis $25 million, under certain circumstances related to the successful development of Sunesis’ lead product candidate vosaroxin, to acquire a royalty on future worldwide net sales of vosaroxin.


© 2014 Royalty Pharma, RP Management LLC. All Rights Reserved.